A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics

AIMS: Recombinant PEGylated human granulocyte colony‐stimulating factor (pegfilgrastim) is indicated for the reduction of chemotherapy‐induced neutropenia and prevention of febrile neutropenia. Biosimilar pegfilgrastim is expected to reduce the financial burden of this complication of chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Bellon, Anne, Wang, Jessie, Skerjanec, Andrej, Velinova, Maria, Dickerson, Daniel, Sabet, Ahad, Ngo, Ly, O'Reilly, Terry, Tomek, Charles, Schussler, Steven, Schier‐Mumzhiu, Stefanie, Gattu, Sreekanth, Koch, Sven D., Schelcher, Celine, Dobreva, Miryana, Boldea, Anca, Nakov, Roumen, Otto, Gordon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256126/
https://www.ncbi.nlm.nih.gov/pubmed/32022282
http://dx.doi.org/10.1111/bcp.14226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256126/
https://www.ncbi.nlm.nih.gov/pubmed/32022282
http://dx.doi.org/10.1111/bcp.14226

Ejemplares similares